UBS Upgrades InterMune (ITMN) to Neutral
ITMN Hot Sheet
Rating Summary:10 Buy, 4 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 22
UBS upgrades InterMune (Nasdaq: ITMN) from Sell to Neutral. Price target $13.
InterMune, Inc. (InterMune) is a biotech company focused on developing and commercializing therapies in pulmonology and hepatology.
To see more analyst ratings on ITMN Click Here.
InterMune, Inc. (InterMune) is a biotech company focused on developing and commercializing therapies in pulmonology and hepatology.
To see more analyst ratings on ITMN Click Here.
You May Also Be Interested In
- UPDATE: UBS Upgrades Assured Guaranty (AGO) to Buy; Opportunity Opens After Recent Dip on Moody's Review
- UPDATE: Nomura Securities Upgrades Central European Distribution (CEDC) to Neutral; Strategic Alliance with Russian Standard
- Goldman Sachs Upgrades Northrop Grumman (NOC) to Neutral; Coming Back Onto Radar Screens
Create E-mail Alert Related Categories
UpgradesRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
